This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.
Communicating your story to the Street
This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.